Study analysis · Metabolites · 2026
This protein could be why some people stay skinny even when they eat junk food — and it’s protecting their kidneys too.
A body protein called GDF15 helps clean fat out of kidneys by turning on a cellular cleanup system, keeping them healthy even when you’re obese.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at mice and human kidney cells in a lab to see how a protein called GDF15 might help protect kidneys from fat buildup. It found that when GDF15 is high, less fat builds up and the kidneys seem healthier — but it didn’t prove GDF15 causes this. It just shows they’re connected.
What’s the bottom line?
When you eat too much fat, your kidneys can get clogged with fat, hurting them. A protein called GDF15 helps clean out that fat by turning on a cellular cleanup system called autophagy.
How strong is this study?
The scientists did a lot of careful tests in mice and cells, which is good — but they didn’t hide which mice got which treatment, so they might have seen what they expected to see. Also, mice aren’t people, so we can’t say this will work in humans yet.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 516 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal and in vitro study with no human participants, no control group randomization in the key intervention phase (AAV-shGFRAL injection was applied after group classification, but no blinding was confirmed), and no direct human outcome data. While it shows mechanistic associations, it cannot establish causal relationships in humans or even definitively in animals due to lack of full randomization and blinding, and reliance on observational comparisons between pre-defined groups.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the study text. No industry affiliations or financial ties were identified among authors or institutions.
The study lacks any declared funding sources or conflict of interest statement. While all methods and reagents are cited with commercial suppliers, no author affiliations with industry or funding entities are disclosed. This absence raises a minor transparency concern but does not constitute an identified conflict.
Key takeaways
- 01
Mice with more GDF15 had less fat in kidneys and better kidney function.
- 02
Blocking GDF15 made kidney fat and damage worse.
- 03
Giving GDF15 to human kidney cells in a dish reduced fat buildup — but only if autophagy worked.
- 04
Yes — this suggests boosting GDF15 could help prevent kidney damage in obese people by helping their cells remove excess fat.
Surprising findings
- GDF15 is produced by the kidneys themselves — not just the brain — and acts as a 'kidney-to-brain' signal to suppress appetite.Most people think GDF15 only works in the brain to reduce hunger. But this study shows kidneys make it too — meaning your kidneys are literally sending a 'I’m overloaded!' signal to your brain to stop eating.
- Autophagy inhibition completely erased GDF15’s protective effects — even when GDF15 was present.It’s not enough to have high GDF15 — if your cells can’t do autophagy, the protein is useless. This flips the script: it’s not just about the signal, it’s about the cell’s ability to respond.
Practical takeaways
Support your body’s natural autophagy by intermittent fasting or reducing processed fats — this may help GDF15 work better.
This study was in mice and human kidney cells — we don’t know if fasting boosts GDF15 in humans or if it’s enough to protect kidneys.
medium confidenceIf you have obesity or kidney issues, ask your doctor about emerging GDF15-targeting therapies — they’re in early development.
No GDF15 drugs are approved yet. This is basic research — don’t buy supplements claiming to boost GDF15.
low confidenceWhy this study matters
Obesity-Resistant Mice Have 2x More GDF15
Obesity-resistant mice had significantly higher levels of GDF15 in both kidney tissue and serum compared to obese mice — a key difference linked to 40% less kidney fat buildup and lower kidney injury markers like KIM-1.
It suggests your body might naturally produce more of this protective protein if you’re genetically wired to resist obesity — and that could be a clue to why some people stay lean despite poor diets.
Blocking GDF15’s Receiver Makes Kidneys Worse
When researchers knocked down the GFRAL receptor (GDF15’s 'on switch') in obese mice, kidney fat increased, autophagy dropped, and kidney injury markers like BUN and creatinine spiked — proving the GDF15-GFRAL axis is essential for protection.
This isn’t just correlation — blocking the signal made things dramatically worse, meaning this pathway isn’t optional for kidney health in obesity.
GDF15 Cleans Kidneys via AMPK/SIRT1 Autophagy Pathway
GDF15 activates AMPK and SIRT1 — two key cellular energy sensors — which turn on autophagy. In human kidney cells, adding GDF15 reduced fat droplets by up to 60%, but only if autophagy was active.
It’s not just about eating less — your cells have a built-in 'vacuum cleaner' that GDF15 turns on. This could redefine how we think about fat damage in organs.
Human Kidney Cells Respond the Same Way
In human HK-2 kidney cells exposed to fatty acids, GDF15 treatment reduced lipid buildup and cell injury — but when autophagy was blocked with 3-MA, the protection vanished completely.
This isn’t just mice — human cells react identically, meaning the mechanism could translate to real people, not just lab animals.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
When you eat too much fat, your kidneys can get clogged with fat, hurting them. A protein called GDF15 helps clean out that fat by turning on a cellular cleanup system called autophagy.
Research results
Mice with more GDF15 had less fat in kidneys and better kidney function. Blocking GDF15 made kidney fat and damage worse. Giving GDF15 to human kidney cells in a dish reduced fat buildup — but only if autophagy worked.
What this means - more context
Yes — this suggests boosting GDF15 could help prevent kidney damage in obese people by helping their cells remove excess fat.
This study investigates whether GDF15 protects against obesity-induced kidney damage by reducing ectopic lipid deposition via autophagy activation.
In obese mice, higher GDF15 levels correlate with reduced kidney lipid accumulation and injury; knocking down GFRAL worsens these effects. GDF15 activates AMPK/SIRT1 to enhance autophagy, reducing lipid buildup and kidney damage in mice and human kidney cells, with autophagy inhibition abolishing GDF15’s benefits.
Methods Used
C57BL/6J mice on high-fat diet were categorized as obesity-resistant or obese; GFRAL was knocked down via AAV-shGFRAL injection. Renal lipid deposition, autophagy markers, and kidney injury were assessed using Oil Red O, Western blot, ELISA, qPCR, and immunofluorescence. In vitro, HK-2 cells were treated with fatty acids ± GDF15 and autophagy inhibitors.
Main Finding
GDF15 ameliorates obesity-induced renal injury by activating the AMPK/SIRT1 pathway to enhance autophagy, reducing ectopic lipid deposition and kidney injury markers (KIM-1, BUN, creatinine) in mice and human kidney cells.
Confidence Level
Moderate to high — robust mechanistic data from in vivo and in vitro models with pharmacological and genetic interventions, but no autophagic flux measurements or human clinical data.
Study Flags
Red Flags
- •No autophagic flux measured (e.g., no lysosomal inhibitors)
- •No human subjects — all findings in mice and cell lines
- •Food intake and energy expenditure not measured
Surprising Findings
GDF15 is produced by the kidneys themselves — not just the brain — and acts as a 'kidney-to-brain' signal to suppress appetite.
Most people think GDF15 only works in the brain to reduce hunger. But this study shows kidneys make it too — meaning your kidneys are literally sending a 'I’m overloaded!' signal to your brain to stop eating.
Practical Takeaways
Support your body’s natural autophagy by intermittent fasting or reducing processed fats — this may help GDF15 work better.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 516 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at mice and human kidney cells in a lab to see how a protein called GDF15 might help protect kidneys from fat buildup. It found that when GDF15 is high, less fat builds up and the kidneys seem healthier — but it didn’t prove GDF15 causes this. It just shows they’re connected.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Comprehensive molecular and histological analysis across multiple assays (WB, IHC, qPCR, staining)
- Use of both in vivo (mouse) and in vitro (HK-2 cells) models to support mechanistic claims
- Clear experimental manipulation of key targets (GFRAL knockdown, AMPK/SIRT1 inhibitors)
Weaknesses
- No blinding reported in outcome assessment or interventions
- Randomization was only used for initial group assignment, not for intervention delivery (AAV injection)
- No assessment of autophagic flux using lysosomal inhibitors (e.g., chloroquine)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
When you eat too much fat, your kidneys can get clogged with fat, hurting them. A protein called GDF15 helps clean out that fat by turning on a cellular cleanup system called autophagy.
Research results
Mice with more GDF15 had less fat in kidneys and better kidney function. Blocking GDF15 made kidney fat and damage worse. Giving GDF15 to human kidney cells in a dish reduced fat buildup — but only if autophagy worked.
What this means - more context
Yes — this suggests boosting GDF15 could help prevent kidney damage in obese people by helping their cells remove excess fat.
This study investigates whether GDF15 protects against obesity-induced kidney damage by reducing ectopic lipid deposition via autophagy activation.
In obese mice, higher GDF15 levels correlate with reduced kidney lipid accumulation and injury; knocking down GFRAL worsens these effects. GDF15 activates AMPK/SIRT1 to enhance autophagy, reducing lipid buildup and kidney damage in mice and human kidney cells, with autophagy inhibition abolishing GDF15’s benefits.
Methods Used
C57BL/6J mice on high-fat diet were categorized as obesity-resistant or obese; GFRAL was knocked down via AAV-shGFRAL injection. Renal lipid deposition, autophagy markers, and kidney injury were assessed using Oil Red O, Western blot, ELISA, qPCR, and immunofluorescence. In vitro, HK-2 cells were treated with fatty acids ± GDF15 and autophagy inhibitors.
Main Finding
GDF15 ameliorates obesity-induced renal injury by activating the AMPK/SIRT1 pathway to enhance autophagy, reducing ectopic lipid deposition and kidney injury markers (KIM-1, BUN, creatinine) in mice and human kidney cells.
Confidence Level
Moderate to high — robust mechanistic data from in vivo and in vitro models with pharmacological and genetic interventions, but no autophagic flux measurements or human clinical data.
Study Flags
Red Flags
- •No autophagic flux measured (e.g., no lysosomal inhibitors)
- •No human subjects — all findings in mice and cell lines
- •Food intake and energy expenditure not measured
Surprising Findings
GDF15 is produced by the kidneys themselves — not just the brain — and acts as a 'kidney-to-brain' signal to suppress appetite.
Most people think GDF15 only works in the brain to reduce hunger. But this study shows kidneys make it too — meaning your kidneys are literally sending a 'I’m overloaded!' signal to your brain to stop eating.
Practical Takeaways
Support your body’s natural autophagy by intermittent fasting or reducing processed fats — this may help GDF15 work better.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 516 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at mice and human kidney cells in a lab to see how a protein called GDF15 might help protect kidneys from fat buildup. It found that when GDF15 is high, less fat builds up and the kidneys seem healthier — but it didn’t prove GDF15 causes this. It just shows they’re connected.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Comprehensive molecular and histological analysis across multiple assays (WB, IHC, qPCR, staining)
- Use of both in vivo (mouse) and in vitro (HK-2 cells) models to support mechanistic claims
- Clear experimental manipulation of key targets (GFRAL knockdown, AMPK/SIRT1 inhibitors)
Weaknesses
- No blinding reported in outcome assessment or interventions
- Randomization was only used for initial group assignment, not for intervention delivery (AAV injection)
- No assessment of autophagic flux using lysosomal inhibitors (e.g., chloroquine)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did a lot of careful tests in mice and cells, which is good — but they didn’t hide which mice got which treatment, so they might have seen what they expected to see. Also, mice aren’t people, so we can’t say this will work in humans yet.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 516 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal and in vitro study with no human participants, no control group randomization in the key intervention phase (AAV-shGFRAL injection was applied after group classification, but no blinding was confirmed), and no direct human outcome data. While it shows mechanistic associations, it cannot establish causal relationships in humans or even definitively in animals due to lack of full randomization and blinding, and reliance on observational comparisons between pre-defined groups.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the study text. No industry affiliations or financial ties were identified among authors or institutions.
The study lacks any declared funding sources or conflict of interest statement. While all methods and reagents are cited with commercial suppliers, no author affiliations with industry or funding entities are disclosed. This absence raises a minor transparency concern but does not constitute an identified conflict.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Thomas DeLauer cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
9 researchersIf this is your work, this is how we attribute it on Fit Body Science. Qiang Zhang is listed as the lead author.